SPARC trades higher on the BSE
Sun Pharma Advanced Research Company is currently trading at Rs. 180.40, up by 0.70 points or 0.39% from its previous closing of Rs. 179.70 on the BSE.
The scrip opened at Rs. 179.30 and has touched a high and low of Rs. 185.25 and Rs. 176.50 respectively. So far 344044 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 204.25 on 02-Jun-2025 and a 52 week low of Rs. 108.20 on 23-Mar-2026.
Last one week high and low of the scrip stood at Rs. 189.65 and Rs. 137.00 respectively. The current market cap of the company is Rs. 5854.37 crore.
The promoters holding in the company stood at 65.67%, while Institutions and Non-Institutions held 2.91% and 31.42% respectively.
Sun Pharma Advanced Research Company’s (SPARC) licensing partner -- Ocuvex Therapeutics Inc. has received a Complete Response Letter (CRL) from the United States Food and Drug Administration (USFDA) for the PDP-716 New Drug Application (NDA). The CRL was issued due to inspection findings at the finished product manufacturing facility. The USFDA did not raise any other issues with the PDP-716 NDA.
